Abstract:Protein-tyrosine phosphatase nonreceptor type 22 (PTPN22) is a lymphoid-specific tyrosine phosphatase (LYP), and mutations in the PTPN22 gene are highly correlated with a spectrum of autoimmune diseases. However, compounds and mechanisms that specifically inhibit LYP enzymes to address therapeutic needs to manage these diseases remain to be discovered. Here, we conducted a similarity search of a commercial database for PTPN22 inhibitors and identified several LYP inhibitor scaffolds, which helped identify one highly active inhibitor, NC1. Using noncompetitive inhibition curve and phosphatase assays, we determined NC1's inhibition mode toward PTPN22 and its selectivity toward a panel of phosphatases. We found that NC1 is a noncompetitive LYP inhibitor and observed that it exhibits selectivity against other protein phosphatases and effectively inhibits LYP activity in lymphoid T cells and modulates T-cell receptor signaling. Results from site-directed mutagenesis, fragment-centric topographic mapping, and molecular dynamics simulation experiments suggested that NC1, unlike other known LYP inhibitors, concurrently binds to a "WPD" pocket and a second pocket surrounded by an LYP-specific insert, which contributes to its selectivity against other phosphatases. Moreover, using a newly developed method to incorporate the unnatural amino acid 2-fluorine-tyrosine and 19F NMR spectroscopy, we provide direct evidence that NC1 allosterically regulates LYP activity by restricting WPD-loop movement. In conclusion, our approach has identified a new allosteric binding site in LYP useful for selective LYP inhibitor development; we propose that the 19F NMR probe developed here may also be useful for characterizing allosteric inhibitors of other tyrosine phosphatases.

Protein tyrosine phosphatase inhibitors: a patent review and update (2012–2023)

Druggable targets of protein tyrosine phosphatase Family, viz. PTP1B, SHP2, Cdc25, and LMW-PTP: Current scenario on medicinal Attributes, and SAR insights

Protein kinase C inhibitors: a patent review (2010 - present)

Identification and Structure-Function Analyses of an Allosteric Inhibitor of the Tyrosine Phosphatase PTPN22.

From Tyrosine Kinases to Tyrosine Phosphatases: New Therapeutic Targets in Cancers and Beyond

Ectonucleotidase inhibitors: an updated patent review (2017–2023)

PIM kinase inhibitors: an updated patent review (2016-present)

Protein tyrosine phosphatase 1B in metabolic diseases and drug development

Drugging Protein Tyrosine Phosphatases through Targeted Protein Degradation

Advance in regulatory mechanism research of protein tyrosine phosphatases

Progress with polo-like kinase (PLK) inhibitors: a patent review (2018-present)

Recent advances in the discovery of protein tyrosine phosphatase SHP2 inhibitors

PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.

An updated patent review of AKT inhibitors (2020 - present)

A comprehensive review of protein kinase inhibitors for cancer therapy

Therapeutic potential of targeting protein tyrosine phosphatases in liver diseases

Small Molecules As Potent Protein Tyrosine Phosphatase 1B (PTP1B) Inhibitors Documented in Patents from 2009 to 2013

Innovations and Patent Trends in the Development of USFDA Approved Protein Kinase Inhibitors in the Last Two Decades

Targeting phosphatases: From molecule design to clinical trials

Protein Tyrosine Phosphatases in Metabolism: A New Frontier for Therapeutics

Protein Tyrosine Phosphatase 1B (PTP1B): A Comprehensive Review of Its Role in Pathogenesis of Human Diseases